Neuroprotective Effects of Marine Algae by Pangestuti, Ratih & Kim, Se-Kwon
 
Mar. Drugs 2011, 9, 803-818; doi:10.3390/md9050803 
 
Marine Drugs  
ISSN 1660–3397 
www.mdpi.com/journal/marinedrugs 
Review 
Neuroprotective Effects of Marine Algae 
Ratih Pangestuti 
1 and Se-Kwon Kim 
1,2,* 
1  Marine Biochemistry Laboratory, Department of Chemistry, Pukyong National University, Busan 
608–737, Korea; E-Mail: ratihpangestuti@pknu.ac.kr 
2  Marine Bioprocess Research Center, Pukyong National University, Busan 608–737, Korea 
*  Author to whom correspondence should be addressed; E-Mail: sknkim@pknu.ac.kr; 
Tel.: +82-51-629-7094; Fax: +82-51-629-7099. 
Received: 25 February 2011; in revised form: 12 April 2011 / Accepted: 28 April 2011 /  
Published: 10 May 2011 
 
Abstract: The marine environment is known as a rich source of chemical structures with 
numerous  beneficial  health  effects.  Among  marine  organisms,  marine  algae  have  been 
identified as an under-exploited plant resource, although they have long been recognized as 
valuable sources of structurally diverse bioactive compounds. Presently, several lines of 
studies  have  provided  insight  into  biological  activities  and  neuroprotective  effects  of 
marine  algae  including  antioxidant,  anti-neuroinflammatory,  cholinesterase  inhibitory 
activity and the inhibition of neuronal death. Hence, marine algae have great potential to be 
used for neuroprotection as part of pharmaceuticals, nutraceuticals and functional foods. 
This contribution presents an overview of marine algal neuroprotective effects and their 
potential application in neuroprotection. 
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1. Introduction 
Ninety percent of the world’s living biomass is found in the oceans with marine species comprising 
approximately half of the total global biodiversity [1,2]. This wide diversity of organisms is being 
recognized as a reservoir of potent molecules which are elicited by marine organisms to help them 
survive in the hostile environment [2,3]. Among marine organisms, marine algae have been identified 
as an under-exploited plant resources [4,5]. The term marine algae, as used herein, generally refer to 
marine macroalgae or sometimes referred to as seaweeds. 
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Marine algae can be classified into three classes based on their pigmentation, namely brown, red, 
and  green  algae,  which  are  referred  to  as  Phaeophyceae,  Rhodophyceae,  and  Chlorophyceae, 
respectively  [6].  Since  the  1940s,  production  of  algal  polysaccharides  has  attained  commercial 
significance  through  their  application  as  thickening  and  gelling  agents  for  various  industrial 
applications  [7].  Moreover,  marine  algae  are  recognized  as  rich  sources  of  structurally  diverse 
biologically active compounds with great pharmaceutical and biomedical potential. Researchers have 
revealed  that  marine  algal  originated  compounds  exhibit  various  biological  activities  such  as 
anticoagulant  [8,9],  anti-viral  [10,11],  antioxidant  [12–14],  anti-allergic  [15],  anti-cancer  [16],  
anti-inflammatory [17], anti-obesity [18–20], etc. Furthermore, several scientific studies have provided 
insight into neuroprotective properties of marine algae. Many species of marine algae have long been 
used in food diets as well as traditional remedies in Eastern countries and more recently in Europe and 
America. Hence, marine algae have great potential to be used in neuroprotection [21]. 
In recent years, biological activities, nutritional value, and potential health benefits of marine algae 
have been intensively investigated and reviewed. This review, however, focuses specifically on the 
neuroprotective  effects  of  marine  algae  and  emphasizes  their  potential  application  as  future 
pharmaceutical candidates to prevent neurodegenerative diseases. 
2. Bioactivities and Neuroprotective Effects of Marine Algae 
2.1. Antioxidant 
Oxidative stress is the result of an imbalance between pro-oxidant and antioxidant homeostasis that 
leads to the generation of toxic reactive oxygen species (ROS) [22]. Compared to other parts of our 
body, the central nervous system (CNS) is more sensitive to oxidative stress due to its high oxygen 
consumption  and  lipid  content.  Increased  oxidative  stress  in  the  CNS  will  further  lead  to  lipid 
peroxidation, DNA and protein damage [23]. Oxidative stress in the CNS has been demonstrated to 
involve excitotoxicity and apoptosis, the two main causes of neuronal death. Furthermore, oxidative 
stress has also been implicated the progression of Alzheimer’s disease (AD), Parkinson’s disease (PD), 
multiple  sclerosis  (MS)  and  other  neurodegenerative  diseases  [24,25].  Antioxidants  may  have  a 
positive effect in the CNS and seem to be a promising approach of neuroprotection therapy, as they 
can protect the CNS against free radical mediated oxidative damage [26]. However, our endogenous 
antioxidant defenses are not always completely effective and exposure to damaging environmental 
factors is increasing, therefore it seems reasonable to propose that exogenous antioxidants could be 
effective in diminishing the cumulative effects of oxidative damage. Presently, antioxidants constitute 
a major component of clinical and experimental drugs that are currently considered for prevention of 
neurodegenerative diseases and therapy [27].  
Antioxidant  activities  of  marine  algae  have  been  determined  by  various  methods  such  as  
1,1-diphenyl-2-picryl  hydrazyl  (DPPH)  radical  scavenging,  2,2’-azinobis-3-ethylbenzo  
thizoline-6-sulphonate (ABTS) radical scavenging, singlet oxygen quenching activity, lipid peroxide 
inhibition,  superoxide  and  hydroxyl  radical  scavenging  assays.  Lim  et  al.  demonstrated  that 
Neorhodomela aculeate, which is also known as Rhodomela confervoides, was able to scavenge DPPH 
with an IC50 = 90 μg/mL and at a concentration of 20 μg/mL completely suppressed H2O2 induced Mar. Drugs 2011, 9                        
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lipid peroxidation in rat brain homogenate [28]. Furthermore, Fallarero et al. showed that Halimeda 
incrassata and Bryothamniom triquetrum are potent ROS scavengers in mouse hypothalamic (GT1–7) 
cells [29]. Novoa et al. reported that the antioxidant and ROS scavenging activity of B. triquetrum are 
related to their high phenolic contents [30]. Dieckol, a phenolic compound isolated from brown algae 
has been shown to scavenge ROS production in murine microglia (BV2) cells [31]. Wijesekara and 
Kim reported that most phenolic compounds which were purified from marine algae are responsible 
for  marine  algal  antioxidant  activities  and  protective  effects  against  oxidative  stress  induced  cell 
damage [32]. Phenolic compounds act as free radical scavengers, reducing agents and metal chelators, 
and thus effectively inhibit lipid oxidation. In addition, Yan et al. demonstrated that carotenoids have a 
strong radical scavenging activity and are found as a major antioxidant in marine algae [33,34]. Young 
and Lowe indicated that structure, physical form, location or site of action, potential interaction with 
another antioxidant, concentration and partial pressure to oxygen may affect the antioxidant activities 
of carotenoids in biological systems [35]. Fucoxanthin obtained from Padina tetrastromatic has shown 
higher potential to be used as an antioxidant than β-carotene in modulating antioxidant enzyme in 
plasma  and  liver  of  retinol  deficient  rats  [36,37].  However,  the  exact  mechanisms  of  action  how 
fucoxanthin exerts antioxidative effect in rat induced by retinol deficiency are not  yet  completely 
understood. Moreover, the cytoprotective effect of fucoxanthin against ROS formation induced by 
H2O2 in monkey kidney fibroblast (Vero) cells has been observed [38]. Two hydroxyl groups present 
in the ring structure of fucoxanthin may correlate to the inhibition of ROS formation. Indeed, it has 
been reported that the number of hydroxyl groups on the ring structure is correlated with the effects of 
ROS suppression. Moreover, it has also been shown that some marine algal sulfated polysaccharides 
(SPs) can be used as potent antioxidants [39,40]. Antioxidant activity of marine algal SPs depends on 
their structural features such as degree of sulfating, molecular weight, type of the major sugar and 
glycosidic  branching  [41,42].  However,  bioactivities  of  marine  algal  carotenoids  and  SPs  against 
oxidative stress in the CNS have not been demonstrated yet. 
Based  on  those  findings,  it  can  be  suggested  that  among  various  organisms  in  the  marine 
environment, marine algae prove to be one of the useful candidates that can protect the CNS against 
oxidative degradation. Hence, developing novel molecules derived from marine algae which promote 
antioxidant  activity  in  the  CNS  may  lead  to  the  development  of  effective  neuroprotective  agents. 
Furthermore, it is also important to determine whether antioxidants derived from marine algae can be 
used  as  prophylactic  neuroprotective  agents  in  order  to  slow  down  the  progression  of 
neurodegenerative  diseases  in  populations  that  are  at  high  risk,  such  as  the  elderly.  Additionally, 
antioxidant  activities  of  marine  algal  carotenoids,  SPs  and  other  bioactive  compounds  in  the  CNS 
warrant further investigations. 
2.2. Anti-Neuroinflammation 
Inflammation has been found to be the pathophysiological mechanism underlying many chronic 
diseases  such  as  cardiovascular  disease,  diabetes,  certain  cancers,  arthritis,  and  neurodegenerative 
diseases [43]. Recent studies demonstrated that resulting production of inflammatory responses and 
neurotoxic factors in the CNS is sufficient to induce neurodegeneration in a rat model [44]. Several 
cell types have been demonstrated as contributors in inflammation-mediated neurodegeneration, yet Mar. Drugs 2011, 9                        
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microglia are implicated as critical components of the immunological insult to neurons [45]. Microglia 
are  the  immune  cells  in  the  CNS,  they  enters  the  system  from  the  blood  circulation  early  in  an 
organism’s development and serve a role of immune surveillance [43]. Ramified or resting microglia 
constitute 5–20% of glial populations in the CNS [46]. Recent study demonstrated that activation of 
microglia and the resulting production of pro-inflammatory and neurotoxic factors are sufficient to 
induce neurodegeneration in a rat model. Furthermore, activation of microglia and excessive amounts 
of pro-inflammatory mediators release by microglia have been observed during the pathogenesis of 
PD, AD, MS, AIDS dementia complex, as well as post neuronal death in cerebral stroke and traumatic 
brain injury [44,47]. Therefore, a mechanism to regulate inflammatory response release by microglia 
may have important therapeutic potential for the treatment of neurodegenerative diseases.  
Numerous studies has documented anti-inflammatory activities of marine algae in vitro and in vivo [48]. 
However, scientific analysis of anti-neuroinflammatory activity of marine algae has been poorly carried out 
and until now only few studies were reported. Ecklonia cava (Phaeophyceae; Laminareaceae), also known 
as ‘‘sea trumpet”, has been reported to possess anti-inflammatory activity [49–51]. E. cava was able to 
suppress the levels of pro-inflammatory mediators such as nitric oxide (NO), prostaglandine-E2 (PGE2) and 
pro-inflammatory  cytokines  (tumor  necrosis  factor-α  (TNF-α),  interleukin-6  (IL-6)  and  interleukin-1β  
(IL-1β)) in lipopolysaccharides (LPS)-stimulated BV2 cells by blocking nuclear factor-κB (NF-κB) and 
mitogen-activated protein kinases (MAPKs) activation [31,51]. Furthermore, N. aculeate decreased NO 
production  and  inhibiting  inducible  NO  synthase  (iNOS)  expression  in  interferon-gamma  (IFN-γ) 
stimulated BV2 cells [28]. A number of bromophenols have been previously isolated from N. aculeate 
and  may  be  potential  anti-neuroinflammatory  candidates  [52–55].  Another  study  conducted  by  
Cui et al. [56] provide the first evidence that fucoidan isolated from Laminaria japonica has a potent 
inhibitory  effect  against  LPS-induced  NO  production  in  BV2  cells.  In  their  study,  the  average 
molecular weight of fucoidan was 7000 Dalton, consisting of 48% total sugar (including 28% fucose) 
and 29% sulfate. Fucoidan at a concentration of 125 µg/mL, significantly inhibited NO production to 
75% [56]. NO is a cytotoxic, short lived highly diffusible signaling molecule [57]. A number of studies 
demonstrated that NO generated by iNOS causes injury and cell death of neuron and oligodendrocytes 
in the CNS, hence NO is implicated in pathogenesis of various neurodegenerative disease [57,58]. 
Anti-neuroinflammatory activity of another marine algae species, Ulva conglobata has been reported. 
U. conglobata methanolic extracts were able to suppress the expression of pro-inflammatory enzymes, 
iNOS and cyclooxygenase-2 (COX-2), which accounted for the large production of NO and PGE2, 
respectively  [59,60].  Among  other  mediators  released  by  microglia,  NO  and  PGE2  are  the  main 
cytotoxic  mediators  participating  in  the  innate  response  in  the  CNS  [61,62].  Pro-inflammatory 
mediators have been found to be elevated in the brain of early AD [63]. For this reasons, agents that 
inhibit the production of pro-inflammatory mediators have been previously considered as potential 
candidates for the treatment of neurodegenerative diseases. 
Epidemiological studies show that application of non-steroidal anti-inflammatory drugs (NSAIDs) 
reduces the risk and delays the onset of inflammation in the CNS which further participates in the 
pathogenesis of some neurodegenerative diseases. NSAIDs mainly act by inhibiting the production of 
pro-inflammatory mediators. Hence, attenuation of pro-inflammatory mediators in microglia by marine 
algae  demonstrates  its  potential  neuroprotective  activity.  Furthermore,  marine  algae  as  potential  
anti-neuroinflammatory agents have a great potential application in the pharmaceuticals area as well as Mar. Drugs 2011, 9                        
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the  food  industry.  There  are  numerous  advantages  of  marine  algae  use  in  pharmaceuticals  and 
functional foods, such as relatively low production costs, low cytotoxicity, safety and wide acceptability. 
However, further studies are needed with clinical trials for marine algal anti-neuroinflammatory activity. 
2.3. Cholinesterase Inhibitory Activity 
Alzheimer’s  diseases  (AD)  is  an  irreversible,  progressive  neurodegenerative  disease,  which 
resulting  in  memory  loss,  behavior  disturbances,  personality  changes  and  a  decline  in  cognitive 
abilities [64]. It was stated in the cholinergic hypothesis, that a serious loss of cholinergic function in 
the CNS contributes significantly to the cognitive symptoms associated with AD [65]. In accordance, 
neuropathological  studies  demonstrated  that  AD  was  associated  with  deficiency  in  the  brain 
neurotransmitter  acetylcholine  (ACh)  [66].  The  inhibition  of  acetylcholinesterase  (AChE)  enzyme, 
which  catalyzes  the  breakdown  of  ACh,  may  be  one  of  the  most  realistic  approaches  to  the 
symptomatic treatment of AD [67]. Presently, a variety of plants has been reported to possess AChE 
inhibitory activity. Huperzia serrata, a Chinese terrestrial herb has been demonstrated to be a potent 
AChE inhibitor [68]. In addition, Houghton et al. reported cholinesterase (ChE) inhibitory activity of 
Crinum jagus and Crinum glaucum, two Nigerian Crinum species [69]. A number of studies have 
recently  shown  AChE  inhibitory  activity  of  several  marine  algae  species.  A  list  of  marine  algae 
reported to have significant AChE inhibitory activity is presented in Table 1. 
Table 1. Acetylcholinesterase inhibitory activities of several marine algae. 
Marine algae  Extracts/Compounds  IC50  Ref 
Caulerpa racemosa   MeOH extracts  5.5 mg mL
−1  [70] 
Codium capitatum  MeOH extracts  7.8 mg mL
−1  [70] 
Ulva fasciata   MeOH extracts  4.8 mg mL
−1  [70] 
Halimeda cuneata  MeOH extracts  5.7 mg mL
−1  [70] 
Amphiora ephedraea  MeOH extracts  5.1 mg mL
−1  [70] 
Amphiora bowerbankii  MeOH extracts  5.3 mg mL
−1  [70] 
Dictyota humifusa  MeOH extracts  4.8 mg mL
−1  [70] 
Hypnea valentiae  MeOH extracts  2.6 mg mL
−1  [71] 
Padina gymnospora  MeOH extracts  3.5 mg mL
−1  [71] 
Ulva reticulate  MeOH extracts  10 mg mL
−1  [71] 
Gracilaria edulis  MeOH extracts  3 mg mL
−1  [71] 
Ecklonia stolonifera  EtOH extracts  108.11 µg mL
−1  [72] 
Ecklonia stolonifera  24−hydroperoxy−24−vinylcholesterol  389.1 µM  [72] 
Ecklonia stolonifera  Eckstolonol  42.66 µM  [72] 
Ecklonia stolonifera  Eckol  20.56 µM  [72] 
Ecklonia stolonifera  Phlorofucofluoroeckol−A  4.89 µM  [72] 
Ecklonia stolonifera  Dieckol  17.11 µM  [72] 
Ecklonia stolonifera  2−phloroeckol  38.13 µM  [72] 
Ecklonia stolonifera  7−phloroeckol  21.11 µM  [72] 
Ishige okamurae  MeOH extracts  163.07 µM  [73] 
Ishige okamurae  EtOAc extracts  137.25 µM  [73] 
Ishige okamurae  6,6’−bieckol  46.42 µM  [73] 
IC50 values for eserine and galanthamine were 0.004 µ g mL
−1 and 0.0007 mg mL
−1, respectively. Mar. Drugs 2011, 9                        
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Recently, Myung et al. reported that dieckol and phlorofucofluoroeckol possess memory enhancing 
and AChE inhibitory activity [74]. Furthermore, Yoon et al. screened ethanolic extracts of 27 Korean 
marine  algae,  for  inhibitory  activity  on  AChE,  and  found  that  extracts  from  Ecklonia  stolonifera 
showed significant inhibitory activity [72]. Two sterols and eight phlorotannins were isolated from  
E. stolonifera. Eckol, dieckol, 2-phloroeckol and 7-phloroeckol demonstrated selective dose dependent 
inhibitory  activities  toward  AChE;  whereas,  eckstolonol  and  phlorofucofuroeckol-A  exhibited 
inhibitory activities toward both AChE and butyrylcholinesterase (BChE). However, phloroglucinol, 
which is a monomer, and triphlorethol-A, the opened-chain trimer of phloroglucinol, did not inhibit the 
cholinesterase (ChE) at the concentrations tested. The exact mechanisms underlying this phenomenon 
have not yet been identified. However, the possible relation between structure of phlorotannins and 
AChE  inhibitory  activity  has  been  reported,  it  is  suggested  that  phlorotannins  as  polymers  of 
phloroglucinol have appropriately bulky structures, which is then able to mask the ChE and prevents 
the binding of the substrates. Moreover, as the phloroglucinol monomer and open-chain trimer of 
phloroglucinol  were  not  able  to  inhibit  the  ChE  activity,  it  may  suggest  that  that  degree  of 
polymerization and closed-ring structure of phlorotannins play key roles in the inhibitory potential of 
phlorotannins toward the ChE [72]. In addition, Hypnea valentiae and Ulva reticulate, two marine 
algae species from Tamil Nadu, India, also reported to inhibit both AChE and BChE activity [71]. A 
good balance between AChE and BChE activity has been reported to result in higher efficacy for the 
treatment of AD [75]. BChE are considered to play a minor role in regulating brain AChE levels. 
Notably, AChE and BChE mixed inhibition have been found in tacrine and physostigmine, which are 
licensed drugs used in the treatment of AD. 
Taken  together,  marine  red,  brown  and  green  algae  have  potential  to  be  use  as  functional 
neuroprotective  agents  due  to  their  effectiveness  in  inhibiting  ChE  activity.  Furthermore,  some 
compounds  derived  from  marine  algae  provided  mixed  type  ChE  (AChE  and  BChE)  inhibitory 
activities, which have been  considered to be more effective in the treatment of AD.  Some AChE 
synthetic commercial drugs are known to produce side effects. Hence, researchers have a great interest 
to study natural herbs that can act as AChE inhibitors. Many kinds of marine algae, consumed for 
centuries in East Asia countries, are well tolerated and lack harmful side effects. Interestingly, several 
marine  algae  species  have  also  been  demonstrated  as  potential  AChE  inhibitors.  Hence,  AChE 
inhibitory  activity  of  marine  algae  should  be  screened  and  further  studies  with  clinical  trials  are  
also needed. 
2.4. Inhibition of Neuronal Death 
A common pathological hallmark of various neurodegenerative diseases is the loss of particular 
subsets of neurons [76]. Neurodegeneration of these neural subsets may be a consequence of various 
forms of neural cell death, including necrosis and apoptosis [77]. A study carried out by Jhamandas et 
al. successfully showed that fucoidan isolated from Fucus vesiculosus (Figure 1), was able to protect 
rat cholinergic neuronal death induced by Aβ1–42 [78]. Fucoidan pretreatment blocked the activation of 
caspase-9 and caspase-3. Caspase-9 and caspase-3 have been suggested to mediate the terminal stages 
of neuronal apoptosis [79]. Caspase-9 and caspase-3 are two of several central components of the 
machinery  responsible  for  apoptosis.  Therefore,  the  ability  of  fucoidan  to  block  the  activation  of Mar. Drugs 2011, 9                        
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caspase-9 and caspase-3 suggest that inhibition of neuronal death by fucoidan mainly occurs through 
apoptotic inhibition. In neurodegenerative diseases, apoptosis might be pathogenic, and targeting this 
process  might  mitigate  neurodegenerative  diseases  [80].  Furthermore,  aqueous  extracts  of  B. 
triquetrum  has  been  demonstrated  to  protect  GT1–7  cells  death  produced  by  severe  (180  min) 
chemical hypoxia/aglycemia insult, which further reduced the cytotoxicity and early production of free 
radicals. The protection exerted by B. triquetrum extract seems to be linked to its ability to reduce free-
radical generation [81]. The authors suggest that the protective effects of B. triquetrum extract are 
partially related to the presence of ferulic acid [81]. 
Figure 1. Chemical structure of fucoidan isolated from Fucus vesiculosus (Adapted from [39]). 
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2.5. Antineurotoxicity 
Neurotoxins are a varied groups of compounds, whose highly specific effects on the nervous system 
of animals, including humans, is by interfering with nerve impulse transmission [82]. They are able to 
produce  neuronal  damage  or  neurodegeration  when  administered  in  vivo  or  in  vitro  [83].  As  an 
example, β-amyloid (Aβ) peptides have been demonstrated to possess neurotoxic effect on neuron and 
glial  cells  although  the  precise  mechanisms  by  which  this  occurs  have  yet  to  be  elucidated  [84]. 
Excessive accumulation of Aβ in the brain has been characterized as a major pathological hallmark of 
AD and recently, fucoidan has been reported to block Aβ neurotoxicity in neuronal cell [78]. Fucoidan 
treatment abolished the inhibitory effect of Aβ on the phosphorylation of protein kinase C (PKC) 
which has been demonstrated to stimulate the survival of neurons and prevents Aβ neurotoxicity. PKC 
causes GSK-3β inactivation and this inactivation in turn leads to the accumulation of cytoplasmic  
β-catenin and the subsequent translocation of β-catenin to the nucleus, causing TCF/LEF-1-dependent 
transcriptional activation of growth and differentiation related genes, which is required to stimulate 
neuronal survival [85]. In addition, Luo et al. showed that fucoidan isolated from L. japonica was able 
to  protect  against  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (MPTP)-induced  neurotoxicity  in 
animal model of Parkinsonism (C57/BL mice) and dopaminergic (MN9D) cells [86]. The mechanisms 
of protection provided by fucoidan may partly relate to its antioxidative activity. Furthermore, the 
results of those studies suggest potential application of fucoidan for PD prevention and or treatment. 
Moreover, the possible roles of alginates to protects human neuronal (NT2) cells against H2O2-induced Mar. Drugs 2011, 9                        
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neurotoxicity  have  previously  been  demonstrated  [87].  H.  incrassata  and  B.  triquetrum  at  a 
concentration of 0.2 mg/mL has been shown to protect methyl mercury-induced neurotoxicity in GT1–
7 cells [29]. Collectively, marine algae and its bioactive compounds can be used for the development 
of new generation therapeutic neuroprotective agents against neurotoxins in the CNS. 
2.6. Other Neuroprotective Activities 
Neurite  outgrowth  is  a  fundamental  neuronal  feature  and  plays  an  important  role  in  neuronal 
development during embryogenesis and in the adult brain [88]. Sargassum macrocarpum and its two 
active component, sargaquinoic acid and sargachromechanol, have been shown to promote neurite 
outgrowth in rat pheochromocytoma (PC12) cells [89–91]. Structure and neurite outgrowth promoting 
relationship of sargaquinoic acid has been reported by Tsang et al. [92]. They reported that quinone is 
the  structural  moiety  of  the  sargaquinoic  acid  molecule  which  is  responsible  for  the  neurite  
outgrowth-promoting activity. Notably, the hydroxyl group bonded to quinone had a significant effect 
on neuritogenic activity. In addition, pheophytin a, a chlorophyll-related compound and its analog, 
vitamin  B12  derived  from  Sargassum  fulvellum  also  has  potential  neurite  outgrowth-promoting  
activity [93,94]. 
Phlorotannins derived from Eisenia bicyclis have been demonstrated to inhibit β-amyloid cleavage 
enzyme (BACE-1) activity [95]. BACE-1 represents candidate biomarkers of AD, since it initiates the 
formation of Aβ [96]. When considering that almost all currently available medications for AD are 
AChE  inhibitors,  suppression  of  BACE-1  by  phlorotannins  will  enhance  the  medications  and  or 
therapy for AD patients. 
In  addition,  Lee  et  al.  demonstrated  that  fucoidan  treatment  resulted  in  an  increase  in  cell 
proliferation of human neuroblastoma (SH-SY5Y) cell induced by Aβ [97]. Hence, it may suggest that 
fucoidan has potential neuroprotective effects. 
3. Prospects of Marine Algae as Neuroprotective Agents 
Neurodegenerative diseases are estimated to surpass cancer as the second most common cause of 
death among elderly by the 2040s [98,99]. For this reason, a great deal of attention has been expressed 
by  scientists  regarding  safe  and  effective  neuroprotective  agents.  Many  categories  of  natural  and 
synthetic neuroprotective agents have been reported. However, synthetic neuroprotective agents are 
believed to have certain side effects such as dry mouth, tiredness, drowsiness, sleepiness, anxiety or 
nervousness, difficulty to balance, etc. [100]. Hence, nowadays researchers have an interest in studying 
natural  bioactive  compounds  that  can  act  as  neuroprotective  agents.  Marine  algae  represent  one 
potential candidate neuroprotective agent. However, development of marine algae as neuroprotective 
agents still faces several challenges. The rationale for marine algal neuroprotective effects treatment in 
the CNS is based on established observations and experiments in vitro or in animal models only. Up to 
now,  none  of  the  marine  algal  neuroprotective  effects  have  been  examined  in  human  subjects. 
Therefore,  small  clinical  studies  and  further  large-scale  controlled  studies  are  needed.  Another 
important challenge in the development of marine algae as neuroprotective agents is that many drugs 
failed  to  provide  real  neuroprotection  in  practice.  Potential  reasons  for  this  failure  include 
inappropriate use of specific neuroprotection/s for a given disease or stage of disease progression or Mar. Drugs 2011, 9                        
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the  use  of  suboptimal  doses  [101].  Hence,  future  studies  are  needed  focusing  on  the  synergistic 
benefits of consuming different marine algae species, recommended doses and timing of intake, and 
preparation methods for marine algal bioactive compounds in order to maximize the desired protective 
effect in the prevention of neurodegenerative diseases. 
It has been reported that neurodegenerative diseases in East Asian countries were lower than in 
Europe (p < 0.0004) [102,103]. Many studies have indicated potential health benefits of marine algae 
consumption [7,104]. Thus, lower incidence of neurodegenerative diseases in East Asia may correlate 
to high fish and marine algae consumption by East Asian populations. More recently, there has been 
growing interest in marine algae and their constituents as functional foods and nutraceuticals with 
potential  health  benefit  effects  as  sources  of  antioxidant  to  reduce  the  risk  of  neurodegenerative 
diseases. Marine algae are an important source of bioactive ingredients that can be applied to many 
aspects of processing healthier foods and developing functional neuroprotective foods.  
In  addition, the wide diversity of marine algae and numerous  undiscovered unique metabolites 
present  in  marine  algae  are  interesting  sources  to  increase  numbers  of  novel  drugs  against 
neurodegenerative  diseases.  However,  large-scale  human  studies  are  required  to  identify  the 
prophylactic and therapeutic neuroprotective effect of marine algae. 
4. Conclusions 
In conclusion, marine algae are a valuable source of neuroprotective agents and could be introduced 
for the preparation of novel functional ingredients in pharmaceuticals and functional foods as a good 
approach  for  the  treatment  and  or  prevention  of  neurodegenerative  disease.  Marine  algae  can  be 
suggested as an alternative source to synthetic ingredients that can contribute to neuroprotection by 
being  a  part  of  pharmaceuticals  and  functional  foods.  Furthermore,  the  wide  range  of  biological 
activities  associated  with  natural  compounds  derived  from  marine  algae  such  as  phlorotannins, 
alginates,  fucoidan,  sargaquinoic  acid,  SPs  and  carotenoids  increase  the  potential  to  expand  the 
neuroprotective effects and health beneficial value of marine algae in the pharmaceutical industry. 
Until  now,  most  of  the  biological  and  neuroprotective  activities  of  marine  algae  and  its  natural 
compounds have been observed in vitro or in mouse model systems. Therefore, further research studies 
are needed in order to investigate marine algae neuroprotective activities in human subjects and further 
in large-scale controlled studies. 
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